BioGend Therapeutics Co., Ltd. - Laporan Laba Rugi (TTM)

BioGend Therapeutics Co., Ltd.
TW ˙ TPEX
NT$ 38.90 ↑1.40 (3.73%)
2024-10-25
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi BioGend Therapeutics Co., Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 1 1 2 3 5 9 13 18 25 31 37 70 81 110 135 133 157 168 180 195
Change (%) -2.59 51.33 58.73 42.86 93.91 41.88 34.70 42.59 24.50 18.59 87.29 16.45 35.13 22.51 -0.89 17.38 7.02 7.11 8.60
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 1 1 1 1 4 6 8 8 7 9 9 14 18 20 24 25 30 37 42 49
Change (%) -43.90 16.31 84.55 198.80 46.26 31.37 0.77 -17.11 27.19 5.24 55.28 30.54 9.74 16.44 7.63 19.90 21.82 12.78 17.00
% of Revenue 82.52 47.52 36.53 42.47 88.83 67.00 62.03 46.41 26.98 27.56 24.46 20.28 22.73 18.46 17.55 19.05 19.46 22.15 23.33 25.13
Gross Operating Profit 0 1 1 2 1 3 5 9 18 23 28 56 63 90 111 108 126 131 138 146
Change (%) 192.40 83.04 43.87 -72.26 472.85 63.22 90.13 94.29 23.50 23.67 97.66 12.87 42.60 23.88 -2.70 16.79 3.45 5.49 6.05
% of Revenue 17.48 52.48 63.47 57.53 11.17 33.00 37.97 53.59 73.02 72.44 75.54 79.72 77.27 81.54 82.45 80.95 80.54 77.85 76.67 74.87
SG&A 40 40 43 45 48 54 57 66 70 76 80 85 91 95 99 107 117 124 134 139
Change (%) 1.21 6.86 5.06 5.63 13.63 6.02 14.53 6.10 8.65 5.96 6.26 6.56 4.73 4.30 8.11 9.19 5.88 8.25 3.51
% of Revenue 2,773.29 2,881.48 2,034.77 1,346.83 995.90 583.60 436.10 370.80 275.93 240.81 215.18 122.08 111.71 86.58 73.71 80.41 74.79 73.99 74.78 71.27
R&D 112 94 102 106 98 113 122 124 155 166 171 178 170 171 149 154 148 129 148 138
Change (%) -15.94 8.61 3.67 -7.99 16.06 7.74 1.93 24.45 7.39 3.05 3.87 -4.50 0.62 -13.12 3.66 -3.94 -12.99 15.04 -6.53
% of Revenue 7,837.13 6,762.89 4,853.70 3,170.08 2,041.86 1,222.07 928.03 702.28 612.95 528.73 459.45 254.81 208.96 155.58 110.34 115.41 94.44 76.78 82.47 70.97
OpEx 153 135 146 153 149 174 188 198 231 251 261 277 279 286 271 287 296 290 324 326
Change (%) -11.71 8.13 4.51 -2.04 16.14 8.05 5.73 16.65 8.36 4.00 6.40 0.69 2.56 -5.24 5.63 3.08 -1.92 11.85 0.67
% of Revenue 10,692.94 9,691.89 6,925.00 4,559.38 3,126.59 1,872.67 1,426.17 1,119.49 915.86 797.11 699.08 397.16 343.41 260.63 201.60 214.87 188.70 172.93 180.57 167.38
Operating Income -151 -134 -144 -149 -145 -164 -174 -181 -206 -219 -223 -208 -198 -177 -137 -153 -139 -122 -145 -131
Change (%) -11.79 7.68 3.71 -3.04 13.57 6.14 3.55 14.11 6.38 1.91 -7.10 -4.61 -10.82 -22.51 12.06 -9.36 -12.01 18.34 -9.18
% of Revenue -10,592.94 -9,591.89 -6,825.00 -4,459.38 -3,026.59 -1,772.67 -1,326.17 -1,019.49 -815.86 -697.11 -599.08 -297.16 -243.41 -160.63 -101.60 -114.87 -88.70 -72.93 -80.57 -67.38
Interest Expense -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0
Change (%) -0.00 -0.00 -0.00 100.00 80.00 44.44 23.08 -18.75 250.00 68.13 38.56 27.36 -2.96 -3.82 -3.57 -4.12 -7.73 -8.37 -9.14
% of Revenue -0.35 -0.36 -0.24 -0.15 -0.21 -0.19 -0.20 -0.18 -0.10 -0.29 -0.41 -0.30 -0.33 -0.24 -0.19 -0.18 -0.15 -0.13 -0.11 -0.09
Net Income -163 -146 -155 -161 -156 -138 -136 -132 -145 -184 -191 -187 -177 -156 -116 -121 -110 -116 -139 -127
Change (%) -10.69 6.63 3.44 -3.13 -10.97 -1.59 -2.78 9.66 26.96 3.58 -2.33 -5.18 -11.65 -25.76 4.19 -9.09 5.95 19.17 -8.42
% of Revenue -11,400.14 -10,451.83 -7,364.52 -4,799.13 -3,254.21 -1,494.07 -1,036.29 -747.93 -575.22 -586.58 -512.32 -267.18 -217.54 -142.23 -86.20 -90.61 -70.18 -69.47 -77.29 -65.18

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista